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Suntmary 
Vaccination of mice with heat shock proteins isolated from tumor cells induces immunity to 
subsequent challenge with those tumor cells the heat shock protein was isolated from but not 
with other tumor cells (Udono, H., and P. K. Srivastava. 1994. J. Immunol. 152:5398-5403). 
The spedficity of this immune response is caused by tumor-derived peptides bound to the heat 
shock proteins (Udono., H., and P. K. Srivastava. 1993.  J. Exit Med. 178:1391-1396). Our ex- 
periments show that a single immunization with the heat shock protein gp96 isolated from 
fl-galactosidase (fl-gal) expressing P815 cells (ofDBA/2 origin) induces cytotoxic T lymphocytes 
(CTLs) specific for B-gal, in addition to minor H  an.tigens expressed by these cells. CTLs can 
be induced in mice that are major histocompatibility complex (MHC) identical to the gp96 donor 
cells (H-2  a) as well as in mice with a different MHC (H-2b). Thus, gp96 is able to induce "cross 
priming" (Matzinger,  P., and M. J. Bevan. 1977. Cell. Iramunol. 33:92-100), indicating that gp96- 
associated peptides are not limited to the MHC class I ligands of the gp96 donor cell. Our data 
confirm the notion that samples of all cellular antigens presentable by MHC class I molecules 
are represented by peptides associated with gp96 molecules of that cell, even if the fitting MHC 
molecule is not expressed.  In addition, we extend previous reports on the in vivo immunoge- 
nicity of peptides associated gp96 molecules to two new groups of antigens, minor H antigens, 
and proteins expressed in the cytosol. 
T 
he  analysis  of  tumor  rejection  antigens  has  led  to 
the identification of heat shock proteins being able to 
induce tumor-specific immunity in mice (1). Since heat shock 
proteins of tumor calls and normal tissue have been found 
to be of identical sequences, their tumor-specific immunoge- 
nicity was not easily understood. Recent experiments have 
provided an explanation to this paradox. Srivastava and col- 
leagues observed that heat shock proteins (HSPs) chaperone 
antigenic peptides able to induce specific immune responses 
(1), although the detailed mechanisms leading to CTL acti- 
vation after immunization with HSPs are not completely un- 
derstood. Apparently, antigen processing and presentation 
by macrophages plays an important role (4). Among the HSPs 
identified to induce tumor specific  immunity are hsp70, hspg0, 
and gp96 (1). Based on the observed association of CTL an- 
tigens with HSPs and supported by their intracellular loca- 
tion, Srivastava and co-workers (5) proposed a model where 
cytosolic- and endoplasmic reticulum (ER)-resident HSPs form 
a relay line chaperoning antigenic peptides from the cytosol 
into the ER and, after transport through the ER membrane, 
are involved in the transfer of peptides onto MHC class I 
molecules. According to our own previous hypothesis on an- 
tigen processing (6,  7),  the peptides should be gradually 
trimmed by cytosolic and ER-resident proteases during this 
transport. For some of the HSPS, like gp96, ATPase and pro- 
teolytic activities have indeed been reported (8). Since HSPs 
are nonpolymorphic proteins, the repertoire of bound pep- 
tides should reflect the repertoire of proteins inside the cell 
and should not be influenced by the MHC expression of the 
cell that the HSPs are isolated from. It should be possible, 
therefore, to induce a specific CTL response in mice of any 
given MHC type with HSPs derived from cells of the same 
or different MHC expression. The latter phenomenon is de- 
scribed as "cross-priming" (3), and it would suggest that HSPs 
play a role in this process,  as proposed by Srivastava et al. 
(5). To test this model, we investigated the capacity of the 
HSP gp96 to induce a specific CTL response against a pro- 
tein that is expressed only in the cytosol of the gp96 donor 
cells. In addition, we tested minor H-specific CTL responses 
after cross-priming of mice with a different MHC type than 
the gp96 donor cells. Our results support and extend the above- 
mentioned hypothesis. 
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Mice and Antibodies.  BALB/c,  DBA/2, BALB.B, 129/Sv,  and 
C57BL/6 mice were obtained from Charles River Wiga (Sulzfeld, 
Germany), and they were maintained in the animal facilities at the 
German Cancer Research Center. Antibodies to gp96 (anti-grp94, 
SPA-850, clone 9G10) were obtained from StressGen Biotechnolo- 
gies  Corp.  (Victoria,  Canada). 
Purification ofgp96,  gp96 was purified as described (1). Briefly, 
P13.1 cells were grown in roller bottles to generate a 60-ml cell 
pellet. This pellet was homogenized in 200 ml of hypotonic buffer 
(30 mM NaHCO3,  0.5  mM PMSF, pH  7.1) and centrifuged at 
100,000 g.  The supernatant was  applied to a Con  A-Sepharose 
column and Con A-bound material was eluted with PBS containing 
1 mM MgCI2,  2 mM KCI,  and 6%  cx-methyl-mannoside.  The 
eluate was dialyzed against  5 mM phosphate buffer, pH 7.0, and 
separated by FPLC using a MonoQ column (5/5; Pharmacia Bio- 
tech AB, Uppsala,  Sweden) with a 0-1  M  NaC1 gradient. Frac- 
tions were tested in SDS-PAGE and Western blot using an mAb 
specific for gp96. Fractions containing gp96 as the major protein 
were used for immunizations. The approximate concentration was 
determined by measuring the OD at 280 nm (extinction coefficient 
=  1.0). 
Cell Culture and CTL  Assays.  P815 and P13.1 (9) cells were 
cultured in RPMI 1640 containing 10% FCS, 2-ME, L-glutamine, 
and antibiotics. CTL were generated by intraperitoneal immuniza- 
tion of mice with either 107 irradiated  P13.1 ceUs (200 Gy) in 300 
/~1 PBS or with 30/~g gp96 in 300/~1 PBS.  10 d later,  recipient 
spleens were removed, and the splenocytes  were stimulated with 
minor H-incompatible, irradiated spleen cells (33 Gy) or with the 
synthetic B-gal peptide TPHPARIGL at 1/~M (10). CTL lines were 
generated by weekly restimulations with minor H-incompatible, 
irradiated spleen cells or with syngeneic, irradiated spleen cells and 
synthetic peptides  as described (11). CTL assays were performed 
as described (11) using P815, P13.1, and Con A blasts prepar~ spleen 
cells as targets.  Con A blasts  were generated as described  (12). 
FACS  |  Analysis.  5  x  10  s BALB.B-specific CTL,  generated 
and maintained as described above, were incubated with a 100-fold 
dilution of FITC-conjugated anti-CD4, anti-CD8, or IgG control 
antibodies (Becton Dickinson & Co., Mountain View, CA) for 30 
min on ice, washed three times with PBS/2% FCS, and analyzed 
on FACSort  |  (Becton Dickinson & Co.). 
Results 
Induction  of d-gal-specific  CTL.  To  test  the  hypothesis 
proposed by Srivastava and colleagues that gp96 binds pep- 
tides of cytosolic origin after they had been transported into 
the EIL, we attempted  to induce a  B-gal-spedfic  CTL re- 
sponse after intraperitoneal immunization  of BALB/c mice 
(H-2  a) with gp96 molecules purified from the cell line P13.1 
(H-2d). This cell line is a transfectant of P815 that expresses 
Escherichia coli--derived ~J-gal from a construct without a leader 
sequence allowing only cytosolic expression (9,  13).  Induc- 
tion  of B-gal-specific CTLs  with  gp96,  therefore,  should 
only be possible if B-gal--derived peptides are transported from 
the cytosol into the ER and subsequently bind to gp96 mol- 
ecules. The purification of gp96 was done according to ex- 
isting protocols, and the purity of the preparation was con- 
trolled by SDS-PAGE and Western blot analysis. As shown 
in Fig.  1,  the gp96  material used for immunizations  gives 
a single band in an SDS-PAGE and Western blot. Spleen cells 
Figure  1.  (A)  SDS-PAGE followed by 
blotting on polyvinyldifluoride  membranes 
and Ponceau staining of purified gp96 from 
1>13.1 cells. An identical  pattern was obtained 
after silver staining (data not shown). (B) 
Western blot analysis of the same gp96 ma- 
terial as shown in A with the anti-gp96 mAb 
SPA-850 (StressGen). 
of immunized and untreated control mice were stimulated 
in  vitro  with  the  dominant  H-2d-restricted  ~-gal  T  cell 
epitope,  the  H-2La-restricted  peptide  TPHPARIGL  (10). 
Specific CTL activity after 5 d  of bulk culture was usually 
<20% on P13.1 target cells (data not shown). Therefore, CTL 
were restimulated with the 3-gal-derived peptide for an ad- 
ditional 5 d and tested again on P815 and P13.1 target cells. 
Significant B-gal-specific CTL activity on P13.1 target cells 
was observed in cultures obtained from mice immunized with 
P13.1-derived gp96, whereas spleen cells from untreated mice 
showed no CTL activity (Fig. 2 A). Thus,  gp96 molecules 
from P13.1 cells are able to prime B-gal-specific CTLs in mice, 
and therefore must have been carrying B-gal-derived material. 
A  B 
70 
60 
5o 
_~  40 
o 
8  30 
N  20 
lO 
BALB/c  C57BL/6 
I  I  [  I  I  I 
0.22:1  2.2:1  22:1 
K/T ratio 
l  I  I  I  l  I 
0.22:1  2.2:1  22:1 
K/T ratio 
Figure  2.  CTL activity of mice after immunization with gp96 mole- 
cules. (A) Untreated (open symbols) or P13.1- derived gp96 immunized 
DBA/2 mice (closed  symbols)  were stimulated twice in vitro with B-gal- 
derived  peptides, and CTL were tested on P815 (circles)  or P13.1 (triangles) 
target cells. Spontaneous slCr release was <10%, and specific lysis was 
calculated as described  (11). (/3) Untreated (open  symbols)  or P13.1-derived 
gp96 immunized C57BL/6 mice (closed  symbols) were stimulated twice 
in vitro with BALB.B spleen cells, and CTL were tested on C57BL/6 
(circles)  and BALB.B (triangles)  Con A blasts as target cells. Spontaneous 
release was <18%. 
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if gp96 chaperones antigenic peptides independently of the 
MHC coexpressed in the cell and is therefore able to induce 
CTL responses in mice that do not match the MHC type 
of the gp96 donor cells, we also immunized C57BL/6 mice 
(H-2  b) with gp96 isolated from P13.1 cells (H-2d). 10 d after 
immunization, recipient splenocytes were stimulated with 
irradiated BALB.B spleen cells. P13.1 is of DBA/2 (H-2  a) 
origin. DBA/2 differs from C57BL/6 mice at multiple minor 
H genes. Many of the DBA/2 minor H antigens are also ex- 
pressed by the strains BALB.B and 129/Sv (both H-2b), in- 
cluding antigens encoded in the H-3 and H-4 regions. Thus, 
immunization of C57BL/6 mice with DBA/2-derived cells 
should  prime  BALB.B  and  129/Sv-reactive  CTL  in  the 
recipients,  as shown below. Similarly, DBA/2-derived gp96 
molecules should also prime C57BL/6 mice against BALB.B 
and 129/Sv minor H antigens. As shown in Fig. 2 B, P13.1 
(H-2a)-derived  gp96 was indeed able to generate CTLs that 
recognize minor H  antigens expressed  on BALB.B (H-2  b) 
but not on C57BL/6 (H-2  b) Con A blasts.  Unimmunized 
C57BL/6 mice did not generate a response, as expected, since 
minor H-specific CTL responses require in vivo priming (14). 
To compare the immunogenicity  of the gp96 preparation with 
that of intact P13.1 cells, B6 mice were immunized with ei- 
ther P13.1 cells or P13.1-derived gp96. After 10 d, spleno- 
cytes were stimulated with 129/Sv stimulator cells and the 
CTL activity was tested after 5 d of culture and after two 
rounds ofrestimulation (Fig. 3, A and B). As shown in Fig. 
3 A,  a slightly stronger CTL response was observed after 
immunization with P13.1 cells as compared to immuniza- 
tion with gp96. After restimulation, however, this difference 
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Figure  3.  Comparison of the CTL activity of C57BL/6 mice after im- 
munization with 1)13.1 cells or P13.1-derived gp96  molecules  after  5 d 
of in vitro stimulation (A) and after  two rounds  of weekly in vitro re- 
stimulations  (B) with 129/Sv spleen cells. Mice were immunized with 
P13.1 cells (open) or gp96 molecules (closed) and stimulated  for 5 d with 
129/Sv spleen cells. CTL activity was tested on C57BL/6 (circles) and 129/Sv 
(triangles)  Con A blasts.  Spontaneous  slCr release was <20%. 
could not be detected any more, as shown in Fig. 3 B, since 
both cultures lysed 129/Sv blasts equally well. Again, spleen 
cells from mice that were not immunized showed no CTL 
activity, and after several rounds of restimulation, no growing 
cells were detectable anymore (data not shown). The minor 
H-specific CTL lines induced by cross-priming with gp96 
molecules are CD8 positive, as shown for the BALB.B-specific 
CTL line in Fig.  4. 
Our experiments show that immunizations with gp96 mol- 
ecules induce CD8-positive T cell responses that are roughly 
as effective as immunizations with intact tumor cells. Spleen 
cells, however, which are usually more immunogenic than 
tumor cells, might be expected to be more effective than gp96. 
Discussion 
Firstly, our experiments confirm that the HSP gp96 is com- 
plexed with antigens (15) that are able to induce a specific 
CTL response after intraperitoneal immunization without 
the use of additional adjuvants. These antigens (probably pep- 
tides)  are derived from cellular proteins; in our case, from 
/~-gal or from undefined self-proteins representing minor H 
antigens.  Secondly,  our results demonstrate that the ER- 
resident HSP gp96 carries antigens of cytosolic origin, since 
P13.1 expresses the B-gal gene without a leader sequence (9), 
and gp96 derived from these cells primes/~-gal-specific  CTLs 
in mice. Thirdly, the induction of minor H-specific CTLs 
with gp96 derived from an H-2  a cell in H-2  b mice demon- 
strates  the cross-priming capability of gp96 molecules. 
Since the same gp96 preparation can induce CTL specific 
for different antigens, many different peptides have to be 
bound, most likely in different amounts. This might explain 
the need for additional in vitro restimulations for certain an- 
tigens, as observed for/3-gal-specific CTLs. In addition to 
minor H  antigens and/3-gal, viral antigens and tumor an- 
tigens have been shown to be associated with gp96 and to 
induce a CTL response upon immunization (15). 
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Figure 4.  FACS  |  analysis of minor H-specific CTL induced by immu- 
nization with gp96. A BALB.B specific CTL line was stained with FITC- 
conjugated anti-CD4 (solid line), anti-CD8 (dotted line) antibodies, and con- 
trol IgG (dashed line). 
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the machinery that is responsible for protein degradation and 
peptide loading onto MHC class I molecules. According to 
this hypothesis, gp96 molecules bind peptides of cytosolic 
origin after they have been transported through the ER mem- 
brane in a process involving the transporter associated with 
antigen processing (TAP) molecules. These peptides, being 
the product of the cytosolic part of antigen processing (prob- 
ably involving the proteasome complex), are transported in 
an ATlXdependent manner from gp96 onto MHC class I mol- 
ecules (5). Since no peptides of the correct length required 
for MHC class I presentation have been isolated from total 
cell extracts of MHC-mismatched cells (6) and since the pep- 
tide transporter seems to transport peptides consisting of 9-16 
amino acids (16), we believe that gp96-bound peptides are 
intermediates of antigen processing that require further trim- 
ming inside the ER (7) until they can be presented by MHC 
class I molecules. In addition to peptides transported by the 
TAP molecules, gp96 might also be able to bind peptides 
that enter the ER in a TAP- independent manner or that are 
generated inside the ER. The functions of gp96 during the 
final peptide-trimming events are not known, but the sug- 
gested proteolytic activities of gp96 and other HSPs, including 
ATPase activity (8),  allow the speculation that gp96 itself 
could play an active role in the ER-resident processing of MHC 
class I ligands. One possibility is that gp96 generates the cor- 
rect COOH-termini required for the precursor peptides to 
bind to the COOH-terminal pocket of MHC class I mole- 
cules. The processed peptides would then be transferred onto 
MHC  molecules where the final NH2-terminal trimming 
steps occur, generating peptides of the right size to fit into 
the protecting binding groove, as previously suggested (6). 
The frequent use of hydrophobic COOH-terminal anchor 
residues observed among ligands of many MHC class I mol- 
ecules might therefore also reflect the specificity of members 
of the processing machinery and not solely selection by MHC 
molecules, as has been suggested earlier (17). The possibility 
of gp96 being involved in antigen processing is currently under 
investigation in our laboratory. Alternatively, the role of gp96 
might just be the binding of transported precursor peptides, 
and by doing this, allowing NH2- and/or COOH-terminal 
trimming by ER-resident proteases, but at the same time also 
protecting peptides from complete degradation. The MHC 
class I molecules then might select from the pool of gp96- 
bound precursor peptides, those containing the corresponding 
ligand motifs that allow, after the generation of the correct 
NH2-  and COOH-termini,  binding to  the MHC  class I 
molecules. 
Both models, suggesting either an active role in the trim- 
ming of peptides or a more passive role as a peptide carrier, 
explain the ability of gp96 to cross-prime for minor H  an- 
tigens since they predict the binding of precursor peptides 
independent of the MHC molecules coexpressed in the cell. 
In agreement with the proposed function of gp96 in an- 
tigen processing and presentation, it has been noted that the 
expression of gp96 is upregulated by IFN (18), as reported 
for other molecules of the antigen presentation pathway, such 
as proteins of the proteasome complex (19), the peptide trans- 
porters (20), and MHC molecules themselves (21). The capa- 
bility of gp96 to induce CTL responses across MHC barriers 
without the use of adjuvants underlines its promise as a vac- 
cine (1, 2, 4, 5, 8). A possible application could be the im- 
munization with gp96 molecules isolated from tumor cells, 
expressing nonprivate antigens (22)  or cells infected with 
viruses or intracellular parasites known to induce specific and 
protective CTL responses. 
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